You are here

Approvals, Launches, and New Indications

Scenesse is new treatment for people with rare, painful light sensitivity disease
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
First Oral Formulation in the GLP-1 Class
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Studies Show Reduced Symptoms, Clinical Remission
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
100% of Responders Maintained Response for 12 Months or More
Showed Significant Improvement in Metastasis-Free Survival
May Be Used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Polyangiitis
Otezla Approved for Behçet’s Syndrome
For Diabetic Neuropathic Pain, Fibromyalgia, Partial-Onset Seizures, and More
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Patient Access to Inhaler Use Data Could Improve Asthma Management
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Dupilumab Also Reduces Need for Polyp Surgery and Steroids
Patients Had Improved Lung Function, Fewer Exacerbations
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More